View Older Stories View More Recent Stories

Nov 7, 2022 07:05AM Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022
Nov 4, 2022 07:07AM Ionis Pharmaceuticals (IONS) Reports Positive Phase 2 Results of fesomersen
Nov 4, 2022 07:05AM Ionis announces positive results from fesomersen development program
Oct 26, 2022 07:05AM Ionis to hold third quarter 2022 financial results webcast
Oct 12, 2022 07:05AM Ionis announces plan for new manufacturing facility in Oceanside, Calif.
Sep 23, 2022 02:25AM Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
Sep 20, 2022 08:30AM Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing
Sep 20, 2022 07:30AM Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing
Sep 7, 2022 07:33AM Praxis Precision Medicines (PRAX) Provides Updates on Clinical Stage Pediatric Epilepsy Programs
Sep 7, 2022 06:15AM Ionis Pharmaceuticals (IONS) Presented Positive Phase 3 NEURO-TTRansform Study Results at ISA
Sep 7, 2022 02:30AM Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis
Aug 30, 2022 07:05AM Ionis to present at upcoming investor conferences
Aug 9, 2022 07:00AM Ionis reports second quarter financial results and recent business achievements
Jul 28, 2022 07:05AM Ionis Pharmaceuticals (IONS) Reports Positive Topline Results from Phase 2b Study of fesomersen
Jul 28, 2022 07:05AM Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment
Jul 27, 2022 07:05AM Ionis to hold second quarter 2022 financial results webcast
Jul 26, 2022 07:31AM Ionis Pharmaceuticals (IONS) announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
Jul 26, 2022 07:30AM Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
Jul 20, 2022 07:05AM Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
Jul 13, 2022 07:05AM Ionis to participate in virtual fireside chat at H.C. Wainwright 1st Annual Hereditary Angioedema Conference
Jul 11, 2022 07:05AM Ionis Pharmaceuticals (IONS) partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
Jul 11, 2022 07:05AM Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
Jun 25, 2022 09:05AM Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
Jun 21, 2022 02:00AM Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Jun 15, 2022 07:32AM Biogen (BIIB) Announces New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA
Jun 15, 2022 07:30AM New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)
Jun 13, 2022 07:05AM Ionis Pharmaceuticals (IONS) treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
Jun 13, 2022 07:05AM Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
Jun 3, 2022 05:20AM Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
May 12, 2022 07:05AM Ionis to present at RBC Capital Markets Global Healthcare Conference
May 4, 2022 07:00AM Ionis reports first quarter financial results and recent business achievements
May 2, 2022 07:05AM Ionis to host 2022 virtual Annual Meeting of Stockholders
Apr 20, 2022 07:05AM Ionis to hold first quarter 2022 financial results webcast
Apr 4, 2022 05:51AM Ionis Pharmaceuticals (IONS) Reports Positive Data for ETESIAN Phase 2b Study
Apr 4, 2022 12:15AM Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
Mar 28, 2022 07:30AM Biogen (BIIB) and Ionis (IONS) Report Topline Phase 1 Study Results of Drug in C9orf72
Mar 28, 2022 07:30AM Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Mar 28, 2022 07:30AM Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Mar 28, 2022 07:30AM Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Mar 21, 2022 07:05AM Ionis to present at upcoming investor conferences
Mar 16, 2022 07:17PM Ionis Pharmaceuticals (IONS) Reports Publication of Positive Phase 2 Data for donidalorsen
Mar 16, 2022 07:16PM Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
Mar 14, 2022 07:35AM Biogen (BIIB) Presents Updates Across SMA Research Program
Mar 14, 2022 07:30AM Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
Mar 7, 2022 07:05AM Ionis calls for applications for Janice Wiesman Young Investigator Grant Program
Mar 1, 2022 07:05AM Ionis to present at the Cowen Annual Health Care Conference
Feb 24, 2022 07:00AM Ionis reports fourth quarter and full year 2021 financial results and recent business achievements
Feb 10, 2022 07:05AM Ionis to hold full year 2021 financial results webcast
Jan 31, 2022 07:07AM Pfizer (PFE), Ionis (IONS) announce discontinuation of vupanorsen clinical development program
Jan 31, 2022 07:05AM Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
View More Recent Stories View Older Stories